Izumi Biosciences LLC
Izumi develops oral fixed dose combinations to deliver FDA approved drugs to serious, orphan brain diseases that lack effective treatments
Izumi’s IND-stage product, with patent protection until 2033, combines: 1. reformulated elacridar, a clinical stage penetration enhancer, and 2. imatinib, an FDA approved molecularly targeted therapeutic. The product crosses the blood-organ barrier to treat patients with neurofibromatosis type-1 (NF1). An FDA approved product will offset high direct costs, be prescribed by specialists, and reimbursed by insurers.